OncoMatch

OncoMatch/Clinical Trials/NCT06923787

Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - the PILDI Study

Is NCT06923787 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lidocaine for colon cancer.

Phase 2RecruitingInstitute of Oncology LjubljanaNCT06923787Data as of May 2026

Treatment: LidocaineThere are very few data in the literature on changes in inflammatory markers when lidocaine is administered perioperatively in patients with colorectal cancer. In patients undergoing surgery for colon cancer, the aim is to conduct a double-blind placebo-controlled study to determine differences in levels of pro-inflammatory markers, postoperative pain and opioid analgesic consumption in the first two days after surgery, and the time to first postoperative bowel movement. Groups of patients receiving perioperative lidocaine infusion, high dose dexamethasone or placebo will be compared.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Performance status

ASA 0–3

Prior therapy

Cannot have received: neoadjuvant chemotherapy

Lab requirements

Kidney function

renal disease (hemodialysis, creatinine clearance <30 mL/min) [excluded]

Liver function

severe hepatic impairment (cirrhosis, ascites, bleeding disorders, jaundice, encephalopathy) [excluded]

Cardiac function

cardiac rhythm disturbances (bradycardia < 45 beats/min, complete heart block, use of group III antiarrhythmics), status post cardiac arrest [excluded]

cardiac rhythm disturbances (bradycardia < 45 beats/min, complete heart block, use of group III antiarrhythmics), status post cardiac arrest; severe hepatic impairment (cirrhosis, ascites, bleeding disorders, jaundice, encephalopathy); renal disease (hemodialysis, creatinine clearance <30 mL/min)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify